Skip to main content
Delfa

← All assets

Cannabis Sativa Oil

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

0

Recruiting

0

Completed

1

Sites

1

Countries

1

Endpoints

17

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 17 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2/3
1

Trials by status

Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
14
Behavior / neuropsychiatric
2
Other clinical outcomes
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 1 of 17 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
MedCanDemMEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva

Cannabis Sativa Oil

Alzheimer’s disease, Vascular cognitive impairment / dementia, Mixed / unspecified dementia

Multiple dementia etiologiesPh 2/3Completed1Nov 20241

Showing 1-1 of 1 trials